Please use this identifier to cite or link to this item: http://www.repositorio.ufop.br/jspui/handle/123456789/13833
Title: Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis.
Authors: Costa, Rafaella Rodrigues
Silva, João Augusto Oliveira da
Reis, Thiago Alves Rosa dos
Tavares, Grasiele de Sousa Vieira
Mendonça, Débora Vasconcelos Costa
Freitas, Camila Simões de
Lage, Daniela Pagliara
Martins, Vívian Tamietti
Antinarelli, Luciana Maria Ribeiro
Machado, Amanda Sanchez
Bandeira, Raquel Soares
Ribeiro, Fernanda Ludolf
Santos, Thaís Teodoro de Oliveira
Brito, Rory Cristiane Fortes de
Humbert, Maria Victoria
Souza, Daniel Menezes
Duarte, Mariana Costa
Chávez Fumagalli, Miguel Angel
Roatt, Bruno Mendes
Coimbra, Elaine Soares
Coelho, Eduardo Antônio Ferraz
Keywords: Treatment
Drug repositioning
Miltefosine
Issue Date: 2020
Citation: COSTA, R. R. et al. Acarbose presents in vitro and in vivo antileishmanial activity against Leishmania infantum and is a promising therapeutic candidate against visceral leishmaniasis. Medical Microbiology and Immunology, v. 210, p. 133-147, abr. 2021. Disponível em: <https://link.springer.com/article/10.1007%2Fs00430-021-00707-4>. Acesso em: 10 jun. 2021.
Abstract: Treatment against visceral leishmaniasis (VL) is mainly hampered by drug toxicity, long treatment regimens and/or high costs. Thus, the identifcation of novel and low-cost antileishmanial agents is urgent. Acarbose (ACA) is a specifc inhibitor of glucosidase-like proteins, which has been used for treating diabetes. In the present study, we show that this molecule also presents in vitro and in vivo specifc antileishmanial activity against Leishmania infantum. Results showed an in vitro direct action against L. infantum promastigotes and amastigotes, and low toxicity to mammalian cells. In addition, in vivo experiments performed using free ACA or incorporated in a Pluronic® F127-based polymeric micelle system called ACA/ Mic proved efective for the treatment of L. infantum-infected BALB/c mice. Treated animals presented signifcant reductions in the parasite load in their spleens, livers, bone marrows and draining lymph nodes when compared to the controls, as well as the development of antileishmanial Th1-type humoral and cellular responses based on high levels of IFN-γ, IL-12, TNF-α, GM-CSF, nitrite and IgG2a isotype antibodies. In addition, ACA or ACA-treated animals sufered from low organ toxicity. Treatment with ACA/Mic outperformed treatments using either Miltefosine or free ACA based on parasitological and immunological evaluations performed one and 15 days post-therapy. In conclusion, data suggest that the ACA/Mic is a potential therapeutic agent against L. infantum and merits further consideration for VL treatment.
URI: http://www.repositorio.ufop.br/jspui/handle/123456789/13833
metadata.dc.identifier.uri2: https://link.springer.com/article/10.1007%2Fs00430-021-00707-4
metadata.dc.identifier.doi: https://doi.org/10.1007/s00430-021-00707-4
ISSN: 1432-1831
Appears in Collections:DECBI - Artigos publicados em periódicos

Files in This Item:
File Description SizeFormat 
ARTIGO_AcarbosePresentsVitro.pdf
  Restricted Access
1,5 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.